37th Annual Meeting • Nov. 8–12, 2022

The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting & Pre-Conference Programs (SITC 2022) provides a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting includes updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.

View Program Schedule

37th Annual Meeting Organizers

  • Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

  • Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

  • Jillian Hunt, AOCNP – Cincinnati Cancer Advisors

  • Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center

  • Ryan J. Sullivan, MD – Massachusetts General Hospital

Annual Program Committee

  • Chair: Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

  • Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

  • Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center

  • Lorenzo Falchi, MD – Memorial Sloan Kettering Cancer Center

  • Michelle Rohlfs, APRN, FANP-BC, AOCNP – The University of Texas MD Anderson Cancer Center

Target Audience

The audience includes basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, who wish to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

Learning Objectives

Upon conclusion of this activity, participants should be able to:

  • Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research

  • Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy

  • Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention

    Continuing Education

    This program will be accredited to offer CME, CNE, CPE and MOC credits.

    SITC's 37th Annual Meeting is supported in part by grants from AbbVie, Inc., Agenus, Inc., Alkermes, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bayer Healthcare Pharmaceuticals Inc., BeiGene USA, Inc., Bristol Myers Squibb, Genmab US, Inc, Immatics Biotechnologies GmbH, Incyte Corporation, Iovance Biotherapeutics, Janssen Pharmaceutical Research & Development, LLC, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Nanobiotix, Novartis Pharmaceuticals Corporation, Personalis, Inc., Pfizer, Inc., and Sanofi US Services, Inc. (as of October 13, 2022)

    SITC Related Resources

    SITC offers a variety of resources about immunology and immunotherapy. Explore the pages below to learn more.